C4 Therapeutics Inc (NASDAQ: CCCC) kicked off on Friday, down -3.20% from the previous trading day, before settling in for the closing price of $2.19. Over the past 52 weeks, CCCC has traded in a range of $1.95-$9.19.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 19.86%. While this was happening, its average annual earnings per share was recorded -21.75%. With a float of $56.70 million, this company’s outstanding shares have now reached $70.63 million.
Let’s determine the extent of company efficiency that accounts for 110 employees. In terms of profitability, gross margin is 82.78%, operating margin of -336.15%, and the pretax margin is -295.6%.
C4 Therapeutics Inc (CCCC) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of C4 Therapeutics Inc is 20.14%, while institutional ownership is 83.17%. The most recent insider transaction that took place on Feb 18 ’25, was worth 2,107. In this transaction Chief Business Officer of this company sold 669 shares at a rate of $3.15, taking the stock ownership to the 107,805 shares. Before that another transaction happened on Feb 14 ’25, when Company’s Chief Business Officer sold 490 for $3.15, making the entire transaction worth $1,544. This insider now owns 110,842 shares in total.
C4 Therapeutics Inc (CCCC) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.37 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -21.75% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.62% during the next five years compared to -8.92% drop over the previous five years of trading.
C4 Therapeutics Inc (NASDAQ: CCCC) Trading Performance Indicators
Take a look at C4 Therapeutics Inc’s (CCCC) current performance indicators. Last quarter, stock had a quick ratio of 5.71. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.23.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.52, a number that is poised to hit -0.46 in the next quarter and is forecasted to reach -1.66 in one year’s time.
Technical Analysis of C4 Therapeutics Inc (CCCC)
Looking closely at C4 Therapeutics Inc (NASDAQ: CCCC), its last 5-days average volume was 0.68 million, which is a drop from its year-to-date volume of 1.57 million. As of the previous 9 days, the stock’s Stochastic %D was 56.38%. Additionally, its Average True Range was 0.18.
During the past 100 days, C4 Therapeutics Inc’s (CCCC) raw stochastic average was set at 3.72%, which indicates a significant decrease from 33.99% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 66.87% in the past 14 days, which was lower than the 76.13% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.04, while its 200-day Moving Average is $4.77. However, in the short run, C4 Therapeutics Inc’s stock first resistance to watch stands at $2.18. Second resistance stands at $2.23. The third major resistance level sits at $2.28. If the price goes on to break the first support level at $2.07, it is likely to go to the next support level at $2.02. Now, if the price goes above the second support level, the third support stands at $1.97.
C4 Therapeutics Inc (NASDAQ: CCCC) Key Stats
The company with the Market Capitalisation of 150.50 million has total of 70,990K Shares Outstanding. Its annual sales at the moment are 35,580 K in contrast with the sum of -105,320 K annual income. Company’s last quarter sales were recorded 5,180 K and last quarter income was -34,570 K.
